drugset / Trial / NCT06932263

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263

Phase 2 Recruiting 540 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

Timeline

Start
2025-03-26
Primary completion
2027-06-07
Completion
2028-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Tozorakimab Monoclonal antibody Subcutaneous

Indications